May 14, 2013
Compiled & Edited by Sue Emerson – Publisher
Prior Edition: May 8, 2013
List of all News/Updates
MEDICATION-ASSISTED TREATMENT (MAT) AND OPIOID ABUSE/ADDICTION
- Titan Pharmaceuticals Receives Complete Response Letter from the FDA for Probuphine New Drug Application
- Vivitrol: A Shot in the Dark
- No Generic Version of Painkiller Oxycontin, U.S. Health Regulators Say
- Neonatal Abstinence Syndrome Linked to Exorbitant Costs
- Genes Found That May Protect Infants Born to Addicted Mothers
- Vaccine Halts Heroin Addiction in Rats
- Legal Interventions to Reduce Overdose Mortality: Naloxone Access and Overdose Good Samaritan Laws
On April 30 Titan Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its New Drug Application (NDA) for Probuphine®, the company’s investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients.
“A single hospital’s costs to treat neonatal abstinence syndrome in infants born to opioid-dependent mothers who received opioid replacement therapy during pregnancy totaled more than $4 million during a 3-year period, a new study shows.
“A vaccine to treat heroin addiction has proven effective in keeping drug-addicted rats from relapsing in a preclinical trial, according to a study published this week in Proceedings of the National Academy of Sciences. Researchers from the Scripps Research Institute in California say the vaccine is now ready for human trials.
The White House Office of National Drug Control Policy (ONDCP) released the 2013 National Drug Control Strategy on April 24. Highlights of the Strategy include:
“Drug courts have made a surprisingly small contribution to the crime reduction that has occurred over the past twenty years. They process only a small fraction of drug-involved offenders within the criminal justice system, and an even smaller fraction of offenders who commit serious crimes. Most chronic cocaine, heroin and methamphetamine users who reach court will end up in jail or prison, often for minor crimes.
This article provides an excellent recap of the second National Rx Drug Abuse Summit held April 2-4, 2013, in Orlando, Florida. Nearly 900 people from 49 states and two other countries attended the conference.
By PDGACO GaballaLoans